Paraganglioma: Not just an extra-adrenal pheochromocytoma

Langenbeck's Archives of Surgery

Volumn 397, Issue 2, 2012, Pages 247-253

  Laird, Amanda M ^a,b   Gauger, Paul G ^a   Doherty, Gerard M ^a   Miller, Barbra S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adrenal; Adrenal cancer; Malignant paraganglioma; Malignant pheochromocytoma; Paraganglioma; Pheochromocytoma

Indexed keywords

SOMATOSTATIN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD; OUTCOME ASSESSMENT; PARAGANGLIOMA; PATIENT INFORMATION; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858867325     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-011-0871-y     Document Type: Article

References (36)

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW (2009) Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 94(6):1853-1878
2. Reisch N, Peczkowska M, Januszewicz A, Neumann HP (2006) Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 24(12):2331-2339 (Pubitemid 44684675)
3. Anderson GH Jr, Blakeman N, Streeten DH (1994) The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12(5):609-615 (Pubitemid 24192887)
4. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004) Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27(3):193-202 (Pubitemid 38489081)
5. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A (2000) A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85 (2):637-644
6. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25(2):309-340 (Pubitemid 38528713)
7. Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366(9486):665-675 (Pubitemid 41176020)
8. Jimenez C, Cote G, Arnold A, Gagel RF (2006) Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 91(8):2851-2858 (Pubitemid 44271723)
9. Welbourn RB (1987) Early surgical history of phaeochromocytoma. Br J Surg 74(7):594-596
10. Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26(5):551-566
11. Sutton MG, Sheps SG, Lie JT (1981) Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 56(6):354-360 (Pubitemid 11093806)
12. Hartley L, Perry-Keene D (1985) Phaeochromocytoma in Queensland - 1970-83. Aust N Z J Surg 55(5):471-475 (Pubitemid 16133944)
13. Linnoila RI, Keiser HR, Steinberg SM, Lack EE (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21(11):1168-1180 (Pubitemid 20382001)
14. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS (1990) Long-term evaluation following resection of apparently benign pheochromocytoma(s)/ paraganglioma(s). World J Surg 14 (3):325-329 (Pubitemid 20299929)
15. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL et al (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229(6):755-764, Discussion 764-756
16. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A et al (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96(3):717-725
17. Maher ER, Eng C (2002) The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 11(20):2347-2354 (Pubitemid 35174697)
18. Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143(6):759-768
19. Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, AgarwalG,VermaAK,Mishra SK, SinghU(2010) Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg 34(12):3022-3028
20. Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, Hahn PF, Boland GW (2004) Pheochromocytoma: an imaging chameleon. Radiographics 24(Suppl 1):S87-S99 (Pubitemid 39457245)
21. Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E (2004) Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 136(6):1129-1137 (Pubitemid 39647525)
22. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM (2010) Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 34(6):1380-1385
23. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12(3):667-680 (Pubitemid 41483000)
24. Shen WT, Grogan R, Vriens M, Clark OH, Duh QY (2010) One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg 145(9):893-897
25. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14(3):569-585 (Pubitemid 350074048)
26. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, Young WF Jr (2001) Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86(11):5210-5216 (Pubitemid 33070237)
27. John H, ZieglerWH, Hauri D, Jaeger P (1999) Pheochromocytomas: can malignant potential be predicted? Urology 53(4):679-683 (Pubitemid 29163029)
28. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, Takano K (2009) Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 94(8):2850-2856
29. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER, Plouin PF (2006) Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 65 (6):699-705 (Pubitemid 44773690)
30. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459-1466 (Pubitemid 34755714)
31. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A et al (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23(34):8812-8818 (Pubitemid 46211527)
32. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 (8):943-951 (Pubitemid 39097204)
33. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91(11):4505-4509 (Pubitemid 44833431)
34. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, Niccoli P, Gaillard D, Chabrier G, Chabolle F et al (2009) The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 94(8):2817-2827
35. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP et al (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92 (10):3822-3828 (Pubitemid 47607629)
36. Scott HW Jr, Halter SA (1984) Oncologic aspects of pheochromocytoma: the importance of follow-up. Surgery 96(6):1061-1066